Logo 1 Logo 2

Clinical Trial Details

Trial ID: L6645
Source ID: NCT02167061
Associated Drug: Da-1229_01
Title: A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 in Healthy Male Volunteers
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: DA-1229_01|DRUG: E+M|DRUG: DA-1229_01 fast|DRUG: DA-1229_01 fed
Outcome Measures: Primary: Area Under Curve(AUC)last of Evogliptin and Metformin, 1d(15d) pre-dose, 1,2,3,4,5,6,7,8,10,12,15,24,36,48,60,72h post-dose|Maximum of concentration (Cmax) of Evogliptin and Metformin, 1d(15d) pre-dose, 1,2,3,4,5,6,7,8,10,12,15,24,36,48,60,72h post-dose | Secondary: Time of maximum concentration(Tmax) of Evogliptin and Metformin, 1d(15d) pre-dose, 1,2,3,4,5,6,7,8,10,12,15,24,36,48,60,72h post-dose|Terminal half-life(t1/2) of Evogliptin and Metformin, 1d(15d) pre-dose, 1,2,3,4,5,6,7,8,10,12,15,24,36,48,60,72h post-dose|Apparent Clearance(CL/F) of Evogliptin and Metformin, 1d(15d) pre-dose, 1,2,3,4,5,6,7,8,10,12,15,24,36,48,60,72h post-dose|Area Under Curve(AUC)inf of Evogliptin and Metformin, AUCinf = AUC last + Clast/λz, 1d(15d) pre-dose, 1,2,3,4,5,6,7,8,10,12,15,24,36,48,60,72h post-dose|Time prior to the first measurable concentration (tlag) of Metformin (only in Part 2 trial), 1d(15d) pre-dose, 1,2,3,4,5,6,7,8,10,12,15,24,36,48,60,72h post-dose
Sponsor/Collaborators: Sponsor: Dong-A ST Co., Ltd.
Gender: MALE
Age: ADULT
Phases: PHASE1
Enrollment: 64
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2014-07
Completion Date: 2014-11
Results First Posted:
Last Update Posted: 2014-12-02
Locations: Clinical Trial Center, Seoul National University Hospital, Seoul, Korea, Republic of
URL: https://clinicaltrials.gov/show/NCT02167061